Rapid In Vivo Validation of HDAC Inhibitor-Based Treatments in Neuroblastoma Zebrafish Xenografts

Rapid In Vivo Validation of HDAC Inhibitor-Based Treatments in Neuroblastoma Zebrafish Xenografts

The survival rate among children with relapsed neuroblastomas continues to be poor, and thus new therapeutic approaches identified by reliable preclinical drug testing models are urgently needed. Zebrafish are a powerful vertebrate model in preclinical cancer research. Here, we describe a zebrafish...

Full description

Bibliographic Details
Main Authors: Jagoda K Wrobel, Sara Najafi, Simay Ayhan, Charlotte Gatzweiler, Damir Krunic, Johannes Ridinger, Till Milde, Frank Westermann, Heike Peterziel, Benjamin Meder, Martin Distel, Olaf Witt, Ina Oehme
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Pharmaceuticals
Subjects:
childhood cancer
preclinical models
precision medicine
xenotransplantation
small molecules
histone deacetylases
Online Access:https://www.mdpi.com/1424-8247/13/11/345

Similar Items

Similar Items